Alacrita’s transatlantic Regulatory Affairs Practice provides auditing, regulatory strategy and due diligence services to life science companies and investors. The Practice, which includes five QPs, has been formed to help pharmaceutical, biotechnology and medtech clients overcome critical regulatory hurdles, devise effective regulatory strategies and provide ongoing, hands-on regulatory support, including assistance with regulatory applications. The team is also supporting companies and investors conducting regulatory due diligence.
All members of the practice are seasoned industry executives who have spent their careers either working within regulatory agencies or shepherding life science products through regulatory processes. Alacrita’s consultants have particular expertise in EU and US regulations and have many years’ experience of interacting with competent authorities in these regions.
The group has deep preclinical and clinical technological experience, covering biologics, pharmaceuticals, API and generics. By pooling our collective experiences and expertise, the team represents a formidable resource for any life science company needing to supplement its in-house regulatory capability.
A world-leading manufacturer of wound care products was assessing opportunities in advanced wound care, and had mapped regulatory pathways relating to various classes of product.
Having identified various paradigms for currently marketed products in the US, including 510(k), Class III PMA, banked human tissue, Biologics License Application, and New Drug Application, the company needed to understand the corresponding regulatory pathways in Europe, and the regulatory requirements for bringing three of its products to market.
For this project, we handpicked a regulatory wound care specialist consultant (who was previously an MHRA assessor) to conduct this project. The final output included:
Further regulatory affairs case studies, performed by Alacrita’s regulatory consultants, are available here.